Director Sells $1.77M in Stock After Option Exercise
LQDA has more than doubled off its 52-week low of $11.85.
Summary
Director Raman Singh exercised stock options and immediately sold the resulting 29,494 shares for $1.77 million, contributing to a pattern of insider sales at Liquidia Corp.
Key Events · Ownership and Investor Activity · LQDA
-
Director Sells Shares
Director Raman Singh sold 29,494 shares of common stock on the open market for a total value of $1,773,435.88.
-
Option Exercise Preceded Sale
The sale followed the exercise of stock options to acquire an equivalent 29,494 shares for $278,351.72, indicating a 'sell-to-cover' transaction.
-
Transaction Price Near 52-Week High
The shares were sold at an average price of $60.13, close to the company's 52-week high of $62.30.
-
Adds to Insider Distribution Trend
This transaction contributes to a recent trend of insider selling at Liquidia Corp, which has seen over $62 million in net insider sales over the past 90 days.
Analysis · LQDA · Life Sciences
Director Raman Singh exercised stock options and immediately sold the acquired shares for approximately $1.77 million. While this type of transaction (often called 'sell-to-cover') is common for liquidity or tax planning, the substantial dollar value of the sale by a director is notable. This transaction adds to a broader pattern of insider distribution at Liquidia Corp, with over $62 million in net insider sales reported in the last 90 days, occurring as the stock trades near its 52-week high. Investors may view this as insiders taking profits.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $60.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $11.85 to $62.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.